The EU Synthetic-Peptide Guideline Is in Force: What It Says and Who It Applies To

On 1 June 2026, an EMA guideline written specifically for chemically synthesised peptides came into effect. In the weeks since, it has started appearing in peptide-vendor marketing as a general quality reference. What tends to go unmentioned is the sentence in its own scope section that decides whether it applies to a given product at all.

This article does the unglamorous thing: it reads the actual document. What the guideline requires, what the numbers in it mean, and, most importantly, who it covers and who it does not.

What Actually Changed on 1 June 2026

Until now, synthetic peptides sat in an awkward regulatory gap. As the guideline itself puts it, they "are at the interface of small molecules and proteins", which sounds like a philosophical observation but has a very concrete consequence: the existing chemistry rulebooks did not fit them. The guideline states plainly that synthetic peptides are "fully or partially excluded from the scope of ICH Q3A/B, ICH Q6A/B and ICH M7", the standard impurity and specification guidelines that a normal small-molecule drug would be assessed against.

A peptide is not a small molecule, because it is far too big and its impurity profile is dominated by things a small molecule never produces. A peptide is also not a biological, because it is made by chemistry rather than by a cell. So for years, a manufacturer submitting a synthetic-peptide dossier in the EU worked from a patchwork of guidance written for neighbouring categories.

EMA/CHMP/CVMP/QWP/367182/2025 fills that gap. It sets out, in the agency's words, "the type of information required for the development, manufacture and control of synthetic peptides (existing or new chemical entities) used in a medicinal product", covering manufacturing (explicitly naming solid-phase peptide synthesis and fragment condensation), characterisation, specifications and analytical control.

The consultation ran from October 2023 to April 2024. The final document was published on 9 December 2025 and became effective on 1 June 2026.

Who It Applies To, and Who It Does Not

This is the section that decides whether everything else in the guideline is relevant to your purchase, and it is the one most likely to be left out when the guideline is cited as a selling point.

So why write about it at all?

Because a guideline does two jobs at once. It sets expectations for the dossiers it governs, and it puts the underlying analytical reasoning on the public record for everyone else. The second part does not stop being informative at the RUO boundary. When EMA writes down which technique answers which question about a peptide, that reasoning is sound chemistry regardless of who is reading it. It gives a research buyer something genuinely useful: a published, citable reference for what a thorough analysis of this class of molecule looks like.

Use it as a yardstick to ask better questions, not as a badge. Reading a certificate against its logic does not make that certificate, or the product behind it, assessed or approved under the guideline.

The Three Numbers That Matter

The most quotable part of the guideline is its impurity thresholds. Three numbers do most of the work, and two of them are explicitly tied to the European Pharmacopoeia.

0.1%, the reporting threshold. The guideline states that "the analytical methods used for the control of impurities should be suitable to fulfil the requirement for the Ph. Eur. reporting threshold of 0.1% for synthetic peptides". In plain terms: your analytical method has to be good enough to see an impurity that makes up one thousandth of the sample. If your method cannot detect it, you cannot claim it is not there.

0.5%, the identification threshold. The Ph. Eur. general monograph "Substances for Pharmaceutical Use" allows an identification threshold of 0.5%, meaning impurities above that level should be identified rather than merely counted. The guideline then adds a demand that goes further: "for comparability purposes a full evaluation of the peptide-related impurity profile at levels 0.1-0.5% is expected". The band between the two numbers is not a free pass.

1.0%, the qualification threshold. This one is subtle and worth understanding, because it is where real chromatograms get messy. The guideline says that "when co-eluting impurities are observed as one peak the qualification threshold of 1.0% applies unless otherwise justified". Co-elution means two different impurities leaving the column at the same time and arriving as a single peak. A purity number cannot see that, because it counts peak area, not the number of compounds inside a peak. The guideline addresses the ambiguity explicitly rather than leaving it to the reader, and leaves the door open to a different figure where it can be justified.

Identity: What Confirms That the Molecule Is the Right One

Purity and identity are different questions, and the guideline separates them cleanly. Purity asks how homogeneous a sample is. Identity asks whether the thing in the vial is the molecule on the label at all. A sample can be 99.8% pure and 100% the wrong peptide.

The guideline lays out which analytical technique answers which question, and it is more granular than the shorthand suggests. For molecular mass, it names MS and LC-MS. For amino-acid sequence confirmation, it names LC-MS/MS of the intact molecule, LC-MS of enzymatically treated material (peptide mapping, for longer peptides), NMR, and Edman degradation. Amino-acid composition is addressed by amino-acid analysis, and enantiomeric purity by chiral GC.

Note that mass and sequence are listed as separate tests. A molecular-mass result narrows down what the molecule can be, but two different peptides can share a mass, so mass alone is not the same as a confirmed sequence. The practical takeaway for anyone reading a CoA is still a short one: if a certificate reports a purity figure from a chromatographic method and nothing about mass or sequence at all, it has answered one question and left the more fundamental one untouched. We cover that distinction in more depth in our guide on peptide quality, and what to check on an actual certificate in our supplier vetting guide.

The Biosimilar Sentence, and Why It Settles an Old Marketing Argument

Buried near the end of the document is a sentence that quietly resolves a claim you will see in peptide marketing, namely that a research peptide is somehow "the same as" or "equivalent to" an approved drug.

The guideline states: "The biosimilar regulatory pathway is not possible for chemically synthesised peptides since these fall outside the definition of a biological substance."

That is unambiguous about one specific thing: the regulatory route. A chemically synthesised peptide cannot go down the biosimilar pathway, because that pathway is defined for biological substances and a synthetic peptide is not one. There is no procedure by which a synthesised copy acquires an approved biological's regulatory status.

The guideline immediately adds a nuance that is worth keeping intact rather than quoting selectively: "Nevertheless, the basic principles to demonstrate biosimilarity, high similarity in terms of structure, biological activity and efficacy, safety and immunogenicity profile, should be considered for synthetic peptide development programmes using a biological medicinal product as a European Reference Medicinal Product."

In other words: the pathway is closed, but the principles still inform development when a synthetic peptide development programme uses a biological medicinal product as its European Reference Medicinal Product. Those are two different statements, and collapsing them is how a technically true sentence becomes a misleading one. Note also what the sentence does and does not settle: it closes a regulatory route. It is not a general verdict on every sense in which two molecules might be called equivalent.

How to Actually Use This When You Read a Certificate

The guideline is not a shopping checklist, and pretending it is would repeat the mistake this article is criticising. But its logic transfers cleanly to the question every research buyer faces: is this certificate telling me anything?

The certificates we hold are published on our lab reports page with the batch number, the testing lab named, and, where the lab provides one, a verification link that resolves on the lab's own server rather than ours. To be precise about our own coverage rather than round it up: at the time of writing that page carries 58 reports covering 30 products, which is most of the catalogue but not all of it. The split matters more than the total. Of those 58 reports, 43 were commissioned by the manufacturer, 12 were submitted by the community, and 3 were commissioned by us (at Liquilabs). We do not run our own testing beyond those three, and we do not describe the other 55 as independent.

What This Guideline Does Not Mean

A short list, because the misreadings are predictable and are already circulating.

It does not mean research peptides are now regulated. The guideline addresses the quality dossier of medicinal products. It does not itself change the rules that apply to research-use-only material. We cover that separately in our guide to the legal landscape.

It does not mean any research supplier is now "EMA approved" or "EMA compliant". There is no such status to acquire. A supplier that is not submitting a medicinal-product dossier is not being assessed against this document at all.

It does not mean a peptide sold for research is now equivalent to an approved drug. The guideline does not address that question. What it does close, explicitly, is the regulatory pathway by which a synthesised peptide could be authorised as a biosimilar of an approved biological.

It does not raise the bar for RUO material by itself. It raises the bar for what a well-informed buyer can reasonably ask for, which is a different and slower mechanism, and ultimately a healthier one.

Products and Categories Referenced

To restate the scope one final time, because this section sits next to product links: the guideline covers synthetic peptides used in medicinal products. The research-use-only products below are outside that scope. They are not assessed under it, not approved under it, and we make no compliance claim for them. They are listed here because their certificates are the ones you can most readily apply this article's questions to.

Longevity & Anti-Aginglongevity

Mitochondrial function, NAD+ metabolism, telomere maintenance

BPC-157regeneration

Gastric pentadecapeptide (15 amino acids) known for exceptional tissue repair properties. Promotes wound healing, angiogenesis, and cytoprotection across tendons, muscles, gut, and nerves. Over 30 years of preclinical research.

TB-500regeneration

Full-length 43-amino-acid Thymosin Beta-4, a naturally occurring repair protein, independently confirmed by a third-party CoA from Janoshik. Promotes cell migration and new blood vessel formation for systemic tissue healing. Especially researched for muscle, tendon, and cardiac repair.

GHK-Culongevity

Naturally occurring copper tripeptide complex for skin regeneration and anti-aging research. Stimulates collagen synthesis, accelerates wound healing, and modulates 4000+ genes. Plasma levels decline with age, making it a key target in longevity research.

SS-31longevity

Mitochondria-targeted tetrapeptide (Elamipretide) that stabilizes cardiolipin and prevents ROS formation at the source.

MOTS-clongevity

Mitochondrial-derived signaling peptide (16 amino acids) that mimics the effects of exercise at the cellular level. Activates AMPK, improves glucose uptake, and enhances fat metabolism - a key tool in metabolic and longevity research.

Frequently Asked Questions

FOR RESEARCH USE ONLY. Not for human consumption. Nothing in this article is medical advice, a therapeutic claim, or a statement of regulatory compliance. EMA/CHMP/CVMP/QWP/367182/2025 addresses synthetic peptides used in medicinal products; the research-use-only materials described on this site are not medicinal products and are not assessed under it.